Drug Trial Radar · NCT06895031
Study of JYP0015 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Last checked: Nov 19, 2026Latest source record: Mar 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
210
Planned (sponsor's estimate)
Start
Mar 31, 2025
Primary completion
Mar 30, 2026
Study completion Dec 31, 2026
Sponsor
- Lead sponsor
- Guangzhou JOYO Pharma Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Mar 26, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Evaluate the safety and antitumor activity of JYP0015 in adults with specific RAS mutant advanced solid tumors.
Conditions
- Solid Tumor
- Pancreatic Ductal Adenocarcinoma (PDAC)
- Non-small Cell Lung Cancer (NSCLC)
- Colorectal Cancer (CRC)
Interventions
JYP0015Drug
JYP0015 is an orally bioavailable pan-RAS inhibitor designed to target the active (ON) form of wild-type and mutant RAS across KRAS, NRAS, and HRAS isoforms. The drug will be administered orally, with dosing determined by the study protocol in the dose-escalation and indication-expansion phases.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Dose-Limiting Toxicity (DLT)Time frame: 21 days
- Incidence and Severity of Treatment-Emergent Adverse Events (AEs) and Serious AEsTime frame: Up to 3 years
- Overall Response Rate (ORR)Time frame: Up to 3 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing Cancer Hospital
Beijing, Beijing Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.